Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Use of Radical Oxygen Species Scavenger Nitrones to Treat Oxidative Stress-Mediated Hearing Loss: State of the Art and Challenges

  • Varela-Nieto, Isabel
  • Murillo-Cuesta, Silvia
  • Rodriguez-de la Rosa, Lourdes
  • Oset-Gasque, María Jesús
  • Marco-Contelles, José
Nitrones are potent antioxidant molecules able to reduce oxidative stress by trapping reactive oxygen and nitrogen species. The antioxidant potential of nitrones has been extensively tested in multiple models of human diseases. Sensorineural hearing loss has a heterogeneous etiology, genetic alterations, aging, toxins or exposure to noise can cause damage to hair cells at the organ of Corti, the hearing receptor. Noxious stimuli share a battery of common mechanisms by which they cause hair cell injury, including oxidative stress, the generation of free radicals and redox imbalance. Therefore, targeting oxidative stress-mediated hearing loss has been the subject of much attention. Here we review the chemistry of nitrones, the existing literature on their use as antioxidants and the general state of the art of antioxidant treatments for hearing loss., This work was supported by FEDER/B2017/BMD- 3688-MULTITARGET&VIEWCM and 0551-PSL-6-E NITROPROHEAR grants to IV-N, and SAF2015-65586-R, PDI-2019-105813RB-C21 grants to JM-C. SM-C and LR hold CIBERER (Institute of Health Carlos III) contracts co-financed with FEDER funds.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities

  • Chrienova, Z.
  • Nepovimova, E.
  • Andrys, R.
  • Dolezal, R.
  • Janockova, Jana
  • Muckova, Lubica
  • Fabova, L.
  • Soukup, Ondrej
  • Oleksak, Patrik
  • Valisa, M.
  • Korabecny, J.
  • Marco-Contelles, José
  • Kuca, K.
Twenty-four novel compounds bearing tetrahydroacridine and N-propargyl moieties have been designed, synthesised, and evaluated in vitro for their anti-cholinesterase and anti-monoamine oxidase activities. Propargyltacrine 23 (IC = 21 nM) was the most potent acetylcholinesterase (AChE) inhibitor, compound 20 (IC = 78 nM) showed the best inhibitory human butyrylcholinesterase (hBChE) profile, and ligand 21 afforded equipotent and significant values on both ChEs (human AChE [hAChE]: IC = 0.095 ± 0.001 µM; hBChE: IC = 0.093 ± 0.003 µM). Regarding MAO inhibition, compounds 7, 15, and 25 demonstrated the highest inhibitory potential towards hMAO-B (IC = 163, 40, and 170 nM, respectively). In all, compounds 7, 15, 20, 21, 23, and 25 exhibiting the most balanced pharmacological profile, were submitted to permeability and cell viability tests. As a result, 7-phenoxy-N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroacridin-9-amine hydrochloride (15) has been identified as a permeable agent that shows a balanced pharmacological profile [IC (hAChE) = 1.472 ± 0.024 µM; IC (hBChE) = 0.659 ± 0.077 µM; IC (hMAO-B) = 40.39 ± 5.98 nM], and consequently, as a new hit-ligand that deserves further investigation, in particular in vivo analyses, as the preliminary cell viability test results reported here suggest that this is a relatively safe therapeutic agent., This work was supported by the project Excellence UHK, by the ERDF/ESF project “PharmaBrain” [No. CZ.02.1.01/0.0/0.0/16_025/0007444], by Long Term Development Plan of University of Hradec Kralove and by a grant of Ministry of Defence “Long Term Development Plan” Medical Aspects of Weapons of Mass Destruction of the Faculty of Military Health Sciences, University of Defence. Additionally, given study was co-financed by ERDF and state budget of the Czech Republic, and by the Ministry of Education, Youth and Sports of Czech Republic [project ERDF IT4N No. CZ.02.1.01/0.0/0.0/18_069/0010054] and SV2105-2020. The study was also supported by Czech Science Foundation [project No. 22-24384S]). RD thanks IT4Innovations for access to the petascale supercomputer Karolina within the project no. OPEN-23–2 supported by the Ministry of Education, Youth and Sports of the Czech Republic through the e-INFRA CZ project [ID:90140]. JMC thanks AEI (Spain Government) [Grant PDI-2019-105813RB-C21] and UCJC [Grant UCJC 2020–33] for support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroprotective and Antioxidant Properties of Different Novel Steroid-Derived Nitrones and Oximes on Cerebral Ischemia In Vitro

  • Izquierdo-Bermejo, Sara
  • Chioua, Mourad
  • Hadjipavlou-Litina, Dimitra
  • López-Muñoz, Francisco
  • Marco-Contelles, José
  • Oset-Gasque, María Jesús
This article belongs to the Special Issue Targeted Pharmacological Modulation of Cellular Pathology and Drug Discovery: A Translational Approach to Bridge Laboratory Discoveries with Clinical Practice, Despite the substantial global impact of ischemic stroke, current therapeutic options remain limited and only partially effective. To advance neuroprotective strategies that could improve the safety and efficacy of existing treatments while preserving brain tissue, we synthesized and evaluated seven new nitrones (MC3, MC5, MC7) and oximes (MC1, MC2, MC4, MC6) derived from different neuroactive steroids—ethisterone (MC1–3), mifepristone (MC4–5) and stanolone (MC6–7)—in an in vitro model of cerebral ischemia. Overall, these derivatives exhibited neuroprotective and antioxidant effects superior to those of the reference compounds cholesteronitrone ChN2, α-tert-butyl nitrone (PBN) and N-acetylcysteine (NAC). Notably, nitrones showed greater neuroprotective, anti-necrotic, and antioxidant potency than their corresponding oximes, regardless of the degree of molecular conjugation. Among them, the stanolone-derived nitrone MC7, which lacks conjugated double bonds, displayed the most balanced and robust profile, consistently enhancing cell viability, reducing necrotic cell death, and suppressing superoxide anion production. Consequently, MC7 has been selected as a promising lead compound for further in vivo studies of cerebral ischemia., This research was supported by grants from the Spanish State Research Agency (AEI) of the Ministry of Science, Innovation and Universities (MICINN) (PDI-2019-105813RB-C21) to J.M-C., and from Camilo José Cela University (UCJC) Grants “CHONICEN” (UCJC 2023-10), “NENS” (UCJC 2022-12) and “HDACi-Stroke” (UCJC 2024-12) to M.J.O.-G. and J.M-C., Peer reviewed